268 related articles for article (PubMed ID: 10942927)
41. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
42. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
[TBL] [Abstract][Full Text] [Related]
43. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
44. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
Tian H; Chen J; Wu Y; Li LL
Ai Zheng; 2008 Jun; 27(6):633-5. PubMed ID: 18570739
[TBL] [Abstract][Full Text] [Related]
46. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
[TBL] [Abstract][Full Text] [Related]
47. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
48. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
[TBL] [Abstract][Full Text] [Related]
49. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Chamorey E; Gressin R; Peyrade F; Rossi JF; Lepeu G; Foussard C; Harrousseau JL; Fabbro M; Richard B; Delwail V; Maisonneuve H; Vilque JP; Thyss A
Oncology; 2005; 69(1):19-26. PubMed ID: 16088231
[TBL] [Abstract][Full Text] [Related]
50. Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Szmigielska-Kapłon A; Błoński JZ; Kasznicki M; Chojnowski K
Chemotherapy; 2005 Aug; 51(5):247-51. PubMed ID: 16088121
[TBL] [Abstract][Full Text] [Related]
51. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Gyan E; Damotte D; Courby S; Sénécal D; Quittet P; Schmidt-Tanguy A; Banos A; Le Gouill S; Lamy T; Fontan J; Maisonneuve H; Alexis M; Dreyfus F; Tournilhac O; Laribi K; Solal-Céligny P; Arakelyan N; Cartron G; Gressin R;
Br J Haematol; 2013 Jul; 162(2):240-9. PubMed ID: 23692641
[TBL] [Abstract][Full Text] [Related]
52. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
53. Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
Wöhrer S; Raderer M; Kaufmann H; Hejna M; Chott A; Zielinski CC; Drach J
Onkologie; 2005 Feb; 28(2):73-8. PubMed ID: 15662110
[TBL] [Abstract][Full Text] [Related]
54. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
[TBL] [Abstract][Full Text] [Related]
55. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
56. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Ballestrero A; Clavio M; Ferrando F; Gonella R; Garuti A; Sessarego M; Ghio R; Gobbi M; Patrone F
Int J Oncol; 2000 Nov; 17(5):1007-13. PubMed ID: 11029505
[TBL] [Abstract][Full Text] [Related]
57. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
[TBL] [Abstract][Full Text] [Related]
58. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Bertini M; Freilone R; Vitolo U; Botto B; Pizzuti M; Gavarotti P; Levis A; Orlandi E; Orsucci L; Pini M
Ann Oncol; 1994 Dec; 5(10):895-900. PubMed ID: 7535080
[TBL] [Abstract][Full Text] [Related]
59. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Nückel H; Dürig J; Dührsen U
Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
[TBL] [Abstract][Full Text] [Related]
60. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
